BIOMAT Database Logo BIOMAT Database Logo

Synthesis and enantiopharmacology of new AMPA-kainate receptor agonists. 1999

P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, v.le Abruzzi, 42-20131 Milano, Italy.

Regioisomeric 3-carboxyisoxazolinyl prolines [CIP-A (+/-)-6 and CIP-B (+/-)-7] and 3-hydroxyisoxazolinyl prolines [(+/-)-8 and (+/-)-9] were synthesized and assayed for glutamate receptor activity. The tests were carried out in vitro by means of receptor binding techniques, second messenger assays, and the rat cortical wedge preparation. CIP-A showed a good affinity for both 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) and kainic acid (KAIN) receptors. These results were confirmed in the cortical slice model where CIP-A displayed an EC(50) value very close to that of AMPA. The convulsant properties of all the compounds were evaluated in vivo on DBA/2 mice after icv injection. CIP-A showed a convulsant activity, measured as tonus and clonus seizures, 18-65 times higher than that produced by AMPA. It was also quite active after ip administration, since it induced seizures in mice at doses as low as 3.2 nmol/mouse. On the basis of the above-reported results we prepared and tested the enantiomers of CIP-A and CIP-B, obtained by reacting (S)-3,4-didehydroproline and (R)-3,4-didehydroproline, respectively, with ethoxycarbonylformonitrile oxide. In all the tests the S-form, CIP-AS [(-)-6], emerged as the eutomer evidencing common stereochemical requirements with the reference compounds AMPA and KAIN. Through modeling studies, carried out on CIP-A, AMPA, and KAIN, active conformations for CIP-AS and AMPA at AMPA receptors as well as for CIP-AS and KAIN at KAIN receptors are suggested.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008297 Male Males
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D003292 Convulsants Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose. They are now most commonly used as experimental tools. Convulsant,Convulsant Effect,Convulsant Effects,Effect, Convulsant,Effects, Convulsant

Related Publications

P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist.
January 2006, Journal of medicinal chemistry,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Synthesis, theoretical and structural analyses, and enantiopharmacology of 3-carboxy homologs of AMPA.
August 2004, Chirality,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists.
October 1999, Journal of medicinal chemistry,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Differences in AMPA and kainate receptor interactomes facilitate identification of AMPA receptor auxiliary subunit GSG1L.
June 2012, Cell reports,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Kainate receptor agonists, antagonists and allosteric modulators.
January 2002, Current pharmaceutical design,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Synthesis and photochemical properties of a kainate precursor and activation of kainate and AMPA receptor channels on a microsecond time scale.
February 1996, Biochemistry,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
April 1996, British journal of pharmacology,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
AMPA/kainate receptor antagonists as novel analgesic agents.
November 1998, Anesthesiology,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis.
July 2020, JCI insight,
P Conti, and M De Amici, and G De Sarro, and M Rizzo, and T B Stensbøl, and H Bräuner-Osborne, and U Madsen, and L Toma, and C De Micheli
Some behavioral effects of AMPA/kainate receptor agonist and antagonists.
September 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,
Copied contents to your clipboard!